Abstract
Although self monitoring of blood glucose is accepted to be effective in lowering Hb A1c levels in insulin-treated diabetic patients, any benefit in non-insulin-treated patients remains controversial. Observational studies cannot answer this question because of either patient self selection (individuals with healthier life styles chose to perform more SMBG) or physician self selection (patients in poorer control are asked to perform SMBG). Only randomized controlled trials (RCTs) can provide the answer. Of the 14 published bona fide RCTs, nine show no benefit in lowering Hb A1c levels. In four of the five positive ones, the SMBG group received more intensive education and/or treatment than the control group. In the one in which patients in both groups were followed similarly, over 500 patients were required to produce a statistically significant difference of 0.2% favoring SMBG, the clinical significance of which is debatable. Thus, there is scant evidence that very expensive SMBG in non-insulin-treated patients is effective in lowering Hb A1c levels. This lack of benefit argues for redirecting these resources into areas of diabetes care where strong evidence exists for improving diabetes outcomes.
Keywords: Self monitoring of blood glucose (SMBG), randomized controlled trials (RCTs), non-insulin-treated patients
Reviews on Recent Clinical Trials
Title: Evaluation of Self Monitoring of Blood Glucose in Non-Insulin-Treated Diabetic Patients by Randomized Controlled Trials: Little Bang for the Buck
Volume: 5 Issue: 3
Author(s): Mayer B. Davidson
Affiliation:
Keywords: Self monitoring of blood glucose (SMBG), randomized controlled trials (RCTs), non-insulin-treated patients
Abstract: Although self monitoring of blood glucose is accepted to be effective in lowering Hb A1c levels in insulin-treated diabetic patients, any benefit in non-insulin-treated patients remains controversial. Observational studies cannot answer this question because of either patient self selection (individuals with healthier life styles chose to perform more SMBG) or physician self selection (patients in poorer control are asked to perform SMBG). Only randomized controlled trials (RCTs) can provide the answer. Of the 14 published bona fide RCTs, nine show no benefit in lowering Hb A1c levels. In four of the five positive ones, the SMBG group received more intensive education and/or treatment than the control group. In the one in which patients in both groups were followed similarly, over 500 patients were required to produce a statistically significant difference of 0.2% favoring SMBG, the clinical significance of which is debatable. Thus, there is scant evidence that very expensive SMBG in non-insulin-treated patients is effective in lowering Hb A1c levels. This lack of benefit argues for redirecting these resources into areas of diabetes care where strong evidence exists for improving diabetes outcomes.
Export Options
About this article
Cite this article as:
B. Davidson Mayer, Evaluation of Self Monitoring of Blood Glucose in Non-Insulin-Treated Diabetic Patients by Randomized Controlled Trials: Little Bang for the Buck, Reviews on Recent Clinical Trials 2010; 5 (3) . https://dx.doi.org/10.2174/157488710792007248
DOI https://dx.doi.org/10.2174/157488710792007248 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Assessing Coronary Blood Flow Physiology in the Cardiac Catheterisation Laboratory
Current Cardiology Reviews The Therapeutic Role of Renin-Angiotensin System Blockers in Obesity- Related Renal Disorders
Current Clinical Pharmacology Diabetes Mellitus, Arterial Stiffness and Cardiovascular Disease: Clinical Implications and the Influence of SGLT2i
Current Vascular Pharmacology Adipose Tissue as a Target of HIV-1 Antiretroviral Drugs. Potential Consequences on Metabolic Regulations
Current Pharmaceutical Design Special Issue on New Cellular, Genetic and Proteomic Tools in the Prevention and Management of Diabetes Mellitus
Current Medicinal Chemistry Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Activity Based Chemical Proteomics: Profiling Proteases as Drug Targets
Current Drug Discovery Technologies Clinical Studies with Sirolimus, Zotarolimus, Everolimus and Biolimus A9 Drug- Eluting Stent Systems
Current Pharmaceutical Design Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiotonic Steroids in Adaptation to Dietary Salt Intake
Current Clinical Pharmacology Cardiovascular Risk and Endothelial Dysfunction: The Preferential Route for Atherosclerosis
Current Pharmaceutical Biotechnology Combination of Daidzein, Hemin and Bms182874 Halts the Progression of Diabetes-Induced Experimental Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Application of Proteomic Tools in Modern Nanotechnological Approaches Towards Effective Management of Neurodegenerative Disorders
Current Drug Metabolism Enriching One’s Environment in the Face of Cognitive and Functional Loss
Current Neurovascular Research New-Onset Posttransplantation Diabetes Mellitus: Insulin Resistance or Insulinopenia? Impact of Immunosuppressive Drugs, Cytomegalovirus and Hepatitis C Virus Infection
Current Diabetes Reviews Islet Purification for Clinical Islet Transplantation
Current Tissue Engineering (Discontinued) Clozapine Safety, 40 Years Later
Current Drug Safety The Etiology of Hypertension in the Metabolic Syndrome Part Two: The Gene-Environment Interaction
Current Vascular Pharmacology Nocturnal Hypertension and Chronic Kidney Disease
Current Hypertension Reviews